Mendus AB (publ) (STO:IMMU)

Sweden flag Sweden · Delayed Price · Currency is SEK
4.305
-0.345 (-7.42%)
Mar 2, 2026, 5:12 PM CET
Market Cap264.11M -30.1%
Revenue (ttm)n/a
Net Income-113.26M
EPS-2.17
Shares Out61.35M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume44,716
Average Volume24,719
Open4.580
Previous Close4.650
Day's Range4.230 - 4.605
52-Week Range4.175 - 10.980
Beta0.76
RSI33.44
Earnings DateFeb 11, 2026

About Mendus AB

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors. Its lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase II CADENCE clinical trial to treat AML; and Phase I ALISON clinical trial for the treatment of ovarian cancers. The company also develops ilixadencel, which is in phase 1/2 clinical trial for the treatment of soft tissue sarcomas; and an NK cell program, which is in a p... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 20
Stock Exchange Nasdaq Stockholm
Ticker Symbol IMMU
Full Company Profile

Financial Performance

Financial Statements